Abstract: An antiinflammatory steroid exhibiting a tendency to crystal growth in suspension in aerosol propellants is contacted with a halogenated hydrocarbon to form a crystalline solvate, which, after removal of some or all of the propellant from the crystals, is reduced to a particle size permitting inhalation into the human bronchial system when dispersed as an aerosol, the micronized crystalline solvate not thereafter exhibiting crystal growth in the aerosol propellant. The solvate is a new composition of matter which has been characterized by I.R. spectra and the aerosol formulation prepared therefrom has valuable therapeutic properties, particularly in the treatment of asthma.

Abstract: Compounds of the general formula 1; ##STR1## in which R.sup.1 and R.sup.5 which may be the same or different represent an alkyl, alkenyl or alkynyl group, which groups may optionally be substituted by an amino, alkylamino or dialkylamino groups, or by hydroxy, alkoxy (C.sub.1-4), aroyl, aryl or aryloxy groups, in which the aroyl, aryl or aryloxy groups may contain an alkoxy (C.sub.1-4) substituent; and R.sup.5 may in addition represent a cycloalkyl group containing from 4 to 8 carbon atoms or a heterocyclic group;R.sup.2 and R.sup.3 which may be the same or different represent a hydrogen atom or an alkyl group;R.sup.4 represents a hydrogen atom or an alkyl group which alkyl group may be substituted by an aryl or aryloxy group which aryl group or aryloxy group may be substituted by an alkoxy (C.sub.1-4) substituent, or R.sup.4 may represent an aryl group which may be substituted by an alkoxy (C.sub.1-4) substituent; and X represents a pharmaceutically acceptable anion of an inorganic or organic acid.

Abstract: Compounds of the general formula (I): ##STR1## in which R.sub.1, R.sub.2 and R.sub.3 may be the same or different and each represents a hydrogen atom, an alkyl group, a nitro group, a halogen atom or a group of the formula --NR.sub.4 R.sub.5 or --OR.sub.4 ; in which the groups R.sub.4 and R.sub.5 may be the same or different and each represent a hydrogen atom, or an alkyl, alkenyl or cycloalkyl group (which alkyl group may optionally be substituted by alkoxy, hydroxy, amino, alkylamino, dialkylamino or aryl groups) or R.sub.4 and R.sub.5 together with the nitrogen atom form a heterocyclic ring which may optionally contain additional hetero atoms, e.g. morpholino or piperazinyl; and R.sub.6 represents a hydrogen atom or an alkyl group.These compounds have biological activity, particularly in inhibiting the release of spasmogenic substances arising as a consequence of antigen-antibody reactions.

Abstract: Novel phenylacetic derivatives are provided of the general formula ##STR1## in which R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined herein, and pharmaceutically acceptable salts thereof. These have anti-inflammatory or analgetic activity. The invention also provides a process for the production of these compounds from a ketone of the structure: ##STR2## It also provides pharmaceutical compositions including phenylacetic derivatives.

Abstract: Compounds of the general formulae I and II and pharmaceutically acceptable salts thereof: ##STR1## in which: R.sub.1 represents a hydrogen atom, a halogen atom, an alkenyl or alkyl group; or a group OR.sub.3 or NR.sub.3 R.sub.4 where R.sub.3 and R.sub.4 which may be the same or different and may represent a hydrogen atom, or an alkenyl group, or an alkyl group which alkyl group may optionally be substituted by one or more hydroxy, alkoxy, acyloxy, aryl, amino, alkylamino, dialkylamino, diaralkylamino or alkylaralkylamino groups; or R.sub.3 and R.sub.4 together with the nitrogen atom form a 5 or 6 membered heterocyclic ring that may optionally contain other hetero atoms.R.sub.2 has the same meanings as R.sub.3.The compounds have utility for the treatment of conditions in which combination of an antigen with a reaginic antibody is primarily responsible.

Abstract: Compounds of the formula: ##STR1## and physiologically acceptable acid addition salts thereof, in which R.sup.1 isA. an arylalkyl group, the alkyl portion of which contains from 1 to 6 carbon atoms and the aryl portion of which may be substituted by one or more alkoxy groups or hydroxy groups; orB. an aryloxyalkyl group, the alkyl portion of which contains from 1 to 6 carbon atoms, and the aryloxy portion of which is substituted with one or more alkoxy or hydroxy groups.These compounds have a blocking action on both .alpha.- and .beta.-adrenergic receptors. Processes for the production of these compounds and pharmaceutical compositions containing them are also provided.

Abstract: Compounds of the formula ##STR1## in which: R.sub.4 and R.sub.5 independently represent hydrogen or lower alkyl;R.sub.6 represents a group Y(CH.sub.2).sub.n, in which n is 2 or 3 andY represents a straight or branched chain alkyl group containing 5 carbon atoms optionally substituted with one more hydroxy or alkoxy groups or by aryl groups which may, in turn, contain hydroxy or alkoxy substituents; orY represents a group ZO--, in which Z represents a straight or branched alkyl group containing from 2 to 6 carbon atoms inclusive substituted by one or more alkoxy, hydroxy, or aryloxy groups; or Z represents an aryl group which may, optionally, contain one or more hydroxy or alkoxy substituents; andR.sub.7 represents a straight or branched alkyl group containing from 3 to 6 carbon atoms, inclusive, optionally substituted by an aryl or aryloxy group which aryl or aryloxy group may, in turn be substituted by hydroxy and alkoxy groupsAnd pharmaceutically acceptable salts thereof.

Abstract: Compounds of the formula: ##STR1## in which: R.sub.4 and R.sub.5 independently represent hydrogen or lowr alkyl;R.sub.6 represents a straight or branched alkyl or alkenyl group containing from 4 to 6 carbon atoms, inclusive, orR.sub.6 represents a straight or branched alkyl group containing from 2 to 6 carbon atoms, inclusive, which alkyl group is substituted by one or more hydroxy, alkoxy or acyloxy groups; or by an aryl group which may be substituted by one or more hydroxy, alkoxy or acyloxy groups as before; andR.sub.7 represents a straight or branched alkyl group containing from 3 to 6 carbon atoms, inclusive, optionally substituted by an alkoxy group or by an aryl or aryloxy group which, alkoxy, aryl or aryloxy group may, in turn be substituted by hydroxy, alkoxy, acetamido or methanesulphonamido groups,And pharmaceutically acceptable salts thereof. These compounds have utility in the treatment of cardiovascular diseases.

Abstract: Compounds of the general formula I: ##STR1## and pharmaceutically acceptable salts thereof in which: A represents the group ##STR2## or the group ##STR3## linked to the adjacent benzene ring through the nitrogen atom, in which R.sub.1 represents a hydrogen atom, or an alkyl group which may optionally be substituted by one or more aryl, aryloxy, alkoxy, acyloxy, amino, alkylamino, dialkylamino or hydroxy groups or represents an alkenyl group;R.sub.2 represents a hydrogen atom, a halogen atom or an alkyl group or the group OR.sub.3, where R.sub.3 is a hydrogen atom or an alkyl group which may optionally be substituted by one or more aryl, aryloxy, alkoxy, acyloxy, hydroxy, amino, alkylamino or dialkylamino groups or the group NR.sub.4 R.sub.5 where R.sub.4 and R.sub.5 may be the same or different and have the meanings given for R.sub.1 or R.sub.4 and R.sub.5 together with the nitrogen atom form a 5 or 6 membered heterocyclic ring which may optionally contain additional hetero atoms;R.sub.6 and R.sub.

Abstract: Compounds of the general formula: ##SPC1##Wherein X represents a 5-[1H]-tetrazolyl group, R.sub.1 represents a hydrogen atom, a halogen atom, a hydroxyl group or a group --OR.sub.2, (in which R.sub.2 may be a lower alkyl or alkenyl group containing from 1 to 6 carbon atoms optionally substituted by one or more hydroxy groups, an aryl group, an aryloxy group, an alkoxy group or a dialkylamino group) or a group --NR.sub.3 R.sub.4, in which R.sub.3 and R.sub.4 which may be the same or different, represent a hydrogen atom, a lower alkyl group containing from 1 to 6 carbon atoms, optionally substituted by a hydroxy group, or R.sub.3 and R.sub.4 together with the nitrogen atom may form a ring which may optionally be substituted with another heteroatom and pharmaceutically acceptable salts thereof.These compounds have useful immunological activity and inhibit the release of spasmogen mediators.

Abstract: Compounds of the general formula: ##SPC1##Wherein X represents a 5-[1H]-tetrazolyl group, R.sub.1 represents a hydrogen atom, a halogen atom, a hydroxyl group or a group --OR.sub.2, (in which R.sub.2 may be a lower alkyl or alkenyl group containing from 1 to 6 carbon atoms optionally substituted by one or more hydroxy groups, an aryl group, an aryloxy group, an alkoxy group or a dialkylamino group) or a group --NR.sub.3 R.sub.4, in which R.sub.3 and R.sub.4 which may be the same or different, represent a hydrogen atom, a lower alkyl group containing from 1 to 6 carbon atoms, optionally substituted by a hydroxy group, or R.sub.3 and R.sub.4 together with the nitrogen atom may form a ring which may optionally be substituted with another heteroatom and pharmaceutically acceptable salts thereof.These compounds have useful immunological activity and inhibit the release of spasmogen mediators.

Abstract: The compound 5,5'-[(2-hydroxytrimethylene)dioxy]bis[2(1H-tetrazol-5-yl)chromone] and non-toxic pharmaceutically acceptable salts thereof.This compound inhibits the release of spasmogen from antibody-antigen reactions.

Abstract: Ethynylbiphenyl derivatives of the general formula (I): ##SPC1##in which R represents a chlorine or bromine atom in the 2, 3 or 4 position. These compounds have anti-inflammatory activity.

Abstract: Compounds of the general formula I: ##EQU1## in which R.sup.1 - R.sup.4 which may be the same or different represent hydrogen atoms, or C.sub.1.sub.-6 straight or branched chain alkyl, alkenyl or alkynyl group or an alkyl group substituted by a cycloalkyl group, or represents a cycloalkyl, alkoxycarbonyl, aryl, arakyl, acyl (which includes anylsulphonyl) groups in which the alkyl group or the alkyl portion of the aralkyl group may be substituted with one or more hydroxy or esterified hydroxy groups and in which the aryl groups or the aryl portion of the acyl or aralkyl group may be substituted by one or more halogen atoms, alkyl groups, hydroxy groups, alkoxy groups, trifluoromethyl, nitro, amino or dialkylamino groups, and in which R.sup.5 - R.sup.8 which may be the same or different represent hydrogen atoms or alkyl groups except that not all groups may be hydrogen, or R.sup.5 and R.sup.6 or R.sup.7 and R.sup.8 together represent a carbonyl (=O) oxygen and in any of the pairs of groups R.sup.1 /R.sup.2, R.

Abstract: Indane derivatives of general formula (I): ##SPC1##in which:R.sub.1 and R.sub.2 represent a hydrogen atom, a lower alkyl group, preferably containing 1 to 6 and particularly 1 to 4 carbon atoms, or an arylalkyl group, or together form a cycloalkyl ring containing 3-6 carbon atoms; R.sub.3 is a hydrogen atom or a lower alkyl preferably containing 1 to 6 and particularly 1 to 4 carbon atoms; R.sub.4 represents the group --NR.sub.5 R.sub.6 in which R.sub.5 and R.sub.6 may be the same or different and each represent a hydrogen atom, a carbamoyl group or a lower alkyl radical preferably containing 1 to 6 and particularly 1 to 4 carbon atoms which may optionally be substituted by amino, alkylamino, dialkylamino, hydroxy, aryl or aroyl groups which aroyl groups may be substituted; or in which R.sub.5 and R.sub.6 may be joined to form a ring optionally containing other hetero atoms; and non-toxic pharmaceutically acceptable salts and esters thereof.

Abstract: A device for testing lung function has a body with two chambers axially separated by a partition. An impeller is rotatably mounted in a first one of the chambers on a shaft extending through the partition into both chambers. An air inlet leads into the first chamber so that air can be blown into the chamber tangentially on to the impeller thereby to rotate the impeller. A reduction gear arranged in the second chamber and is driven by the shaft. An indicator is driven by the reduction gear to indicate the number of revolutions of the impeller.

Abstract: Compounds of the general formulae I and II and pharmaceutically acceptable salts thereof: ##SPC1##In which:R.sub.1 represents a hydrogen atom, a halogen atom, an alkenyl or alkyl group; or a group OR.sub.3 or NR.sub.3 R.sub.4 where R.sub.3 and R.sub.4 which may be the same or different and may represent a hydrogen atom, or an alkenyl group, or an alkyl group which alkyl group may optionally be substituted by one or more hydroxy, alkoxy, acyloxy, aryl, amino, alkylamino, dialkylamino, diaralkylamino or alkylaralkylamino groups; or R.sub.3 and R.sub.4 together with the nitrogen atom form a 5 or 6 membered heterocyclic ring that may optionally contain other hetero atoms.R.sub.2 has the same meanings as R.sub.3.The compounds have utility for the treatment of conditions in which combination of an antigen with a reaginic antibody is primarily responsible.

Abstract: Compounds of the general formula: ##SPC1##In which:R.sub.1 and R.sub.2 which may be the same or different, represent a hydrogen atom or an alkyl group which may optionally be substituted by an aryl group, or represents an alkanoyl, aroyl or alkanesulphonyl group;R.sub.3 represents a hydrogen atom, or an alkyl group which may optionally be substituted by an aryl group, or represents an alkenyl, aryl or alkylthio group;R.sub.4 represents a hydrogen atom or an alkyl group; andR.sub.5 represents a hydrogen atom or an aryl or alkyl group, which alkyl group may optionally be substituted by a cycloalkyl group;And physiologically acceptable salts and derivatives thereof and addition products formed by nucleophilic addition.These compounds act as spasmolytics and phosphodiasterase inhibitors and have cardiotonic and diuretic properties. They are also of use in the treatment of skin disorders and gout.

Abstract: Compounds of the general formula (I): ##SPC1##in which R.sub.1, R.sub.2 and R.sub.3 may be the same or different and each represents a hdyrogen atom, an alkyl group, a nitro group, a halogen atom or a group of the formula --NR.sub.4 R.sub.5 or --OR.sub.4 ; in which the groups R.sub.4 and R.sub.5 may be the same or different and each represent a hydrogen atom, or an alkyl, alkenyl or cycloalkyl group (which alkyl group may optionally be substituted by alkoxy, hydroxy, amino, alkylamino, dialkylamino or aryl groups) or R.sub.4 and R.sub.5 together with the nitrogen atom form a heterocyclic ring which may optionally contain additional hetero atoms, e.g. morpholino or piperazinyl; and R.sub.6 represents a hydrogen atom or an alkyl group.These compounds have biological activity, particularly in inhibiting the release of spasmogenic substances arising as a consequence of antigen-antibody reactions.